2021年欧洲风湿病学协会联盟/美国风湿病学会关于自身炎症性I型干扰素病诊断与管理的考虑要点:CANDLE/PRAAS、SAVI和AGS
该考虑要点由风湿病学家、神经病学家、免疫学家、遗传学家、患者代表等组成的特别工作组制定,基于系统文献综述、德尔菲问卷和共识方法,针对CANDLE/PRAAS、SAVI和AGS三种罕见自身炎症性I型干扰素病提出4项总体原则和17项考虑要点,旨在指导诊断评估、治疗和管理,标准化并改善照护、生活质量和疾病结局。
要点
- 特别工作组制定4项总体原则和17项考虑要点,覆盖CANDLE/PRAAS、SAVI和AGS的诊断、治疗与长期监测。
- 考虑要点基于系统文献综述、德尔菲问卷和共识方法形成,代表当前最新知识。
- 目标为标准化并改善这些罕见自身炎症性I型干扰素病患者的照护、生活质量和疾病结局。
核心结论
- 这些考虑要点代表指导CANDLE/PRAAS、SAVI和AGS诊断评估、治疗和管理的最新知识,旨在标准化并改善照护、生活质量和疾病结局。
研究设计与样本
- 特别工作组由风湿病学家、神经病学家、一名免疫学家、遗传学家、患者代表和一名相关医疗专业人员组成,针对系统文献综述制定研究问题。
- 基于文献、德尔菲问卷和共识方法制定指导患者管理的考虑要点。
主要发现
- 特别工作组制定了4项总体原则和17项考虑要点,涉及自身炎症性I型干扰素病CANDLE/PRAAS、SAVI和AGS患者的诊断、治疗和长期监测。
关键数值与推荐
- 共形成4项总体原则和17项考虑要点,用于CANDLE/PRAAS、SAVI和AGS的诊断、治疗和长期监测。
临床怎么用
- 这些考虑要点代表指导CANDLE/PRAAS、SAVI和AGS诊断评估、治疗和管理的最新知识。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of 'points to consider' to improve diagnosis, treatment and long-term monitoring of patients with these rare diseases. METHODS: Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates and an allied healthcare professional formulated research questions for a systematic literature review. Then, based on literature, Delphi questionnaires and consensus methodology, 'points to consider' to guide patient management were developed. RESULTS: The Task Force devised consensus and evidence-based guidance of 4 overarching principles and 17 points to consider regarding the diagnosis, treatment and long-term monitoring of patients with the autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI and AGS. CONCLUSION: These points to consider represent state-of-the-art knowledge to guide diagnostic evaluation, treatment and management of patients with CANDLE/PRAAS, SAVI and AGS and aim to standardise and improve care, quality of life and disease outcomes.
引用
- Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis. 2022. PMID: 35086813. doi:10.1136/annrheumdis-2021-221814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。